Pharmasset clinical trials
Acquired by Gilead Sciences, Jan 12, 2012 · source ↗
The registry lists 6 studies whose lead sponsor is Pharmasset. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 27, 2009.
Before and after it joined Gilead Sciences
- First submitted before Pharmasset became part of Gilead Sciences
- 6
- First submitted after Pharmasset became part of Gilead Sciences
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Pharmasset6 studies
Something wrong with this grouping? Tell us on the Gilead Sciences page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Gilead Sciences studies →
- Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B VirusTerminatedNCT00496158Phase 3
Sponsor listed in the registry: Pharmasset · First submitted before Pharmasset became part of Gilead Sciences
- Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B VirusTerminatedNCT00496002Phase 3
Sponsor listed in the registry: Pharmasset · First submitted before Pharmasset became part of Gilead Sciences
- Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and RibavirinCompletedNCT00382798Phase 1/2
Sponsor listed in the registry: Pharmasset · First submitted before Pharmasset became part of Gilead Sciences
- Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV SubjectsCompletedNCT00121979Phase 2
Sponsor listed in the registry: Pharmasset · First submitted before Pharmasset became part of Gilead Sciences
- A 14-Day Study of Racivir When Used in Combination in HIV-Infected MalesCompletedNCT00040300Phase 1
Sponsor listed in the registry: Pharmasset · First submitted before Pharmasset became part of Gilead Sciences
- A Study of DPC 817 in HIV-Infected MalesCompletedNCT00040274Phase 1
Sponsor listed in the registry: Pharmasset · First submitted before Pharmasset became part of Gilead Sciences